Try our mobile app

Switch to company model in "Rising Stars" logic    *

General information

Country: UNITED STATES

Sector: Medical Devices

Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company. The company focuses on patients with gastroesophageal reflux disease, which is also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma. Its lead products include EsoGuard, a laboratory developed esophageal DNA test; and EsoCheck, an esophageal cell collection device. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.
Website: luciddx.com


  • Dividend yield for the last twelve months 0.0%
  • Free cash flow yield 159.5% (LTM)
  • Share price is 25.4% higher than minimum and 75.1% lower than maximum for the last 3 years
  • The company is overvalued by EV / LTM EBITDA multiple compared to target level (0.6x vs 0.0x)

Key Financials (Download financials)

Ticker: LUCD
Share price, USD:  (+25.4%)0.411
year average price 1.0526  


year start price 1.2800 2025-10-26

max close price 1.2800 2025-10-26

min close price 0.3277 2026-10-22

current price 0.4110 2026-10-25
Common stocks: 38 138 002

Dividend Yield:  0.0%
EV / Sales: -0.1x
Margin (EBITDA LTM / Revenue): -18.5%

Target EV / EBITDA (hist percentile): 0.0x
EV / LTM EBITDA mutiple calculation
Market Cap ($m): 16
Net Debt ($m): -46
EV (Enterprise Value): -30
EBITDA LTM (млн $): -49
Price to Book: 0.6x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / EBITDA

Potential dynamics

News


2025-11-12seekingalpha.com

Lucid Diagnostics Inc. (LUCD) Q3 2025 Earnings Call Transcript

2025-11-12zacks.com

Lucid Diagnostics Inc. (LUCD) Reports Q3 Loss, Lags Revenue Estimates

2025-09-08seekingalpha.com

Lucid Diagnostics Inc. (LUCD) Investor Conference Call (Transcript)

2025-08-13seekingalpha.com

Lucid Diagnostics Inc. (LUCD) Q2 2025 Earnings Call Transcript

2025-08-13zacks.com

Lucid Diagnostics Inc. (LUCD) Reports Q2 Loss, Tops Revenue Estimates

2025-05-14seekingalpha.com

Lucid Diagnostics Inc. (LUCD) Q1 2025 Business Update Call Transcript

2025-05-14zacks.com

Lucid Diagnostics Inc. (LUCD) Reports Q1 Loss, Lags Revenue Estimates

2025-03-24seekingalpha.com

Lucid Diagnostics Inc. (LUCD) Q4 2024 Earnings Call Transcript

2025-03-24zacks.com

Lucid Diagnostics Inc. (LUCD) Reports Q4 Loss, Lags Revenue Estimates

2024-11-13seekingalpha.com

Lucid Diagnostics Inc. (LUCD) Q3 2024 Earnings Call Transcript
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol LUCD LUCD LUCD LUCD LUCD LUCD LUCD LUCD LUCD LUCD LUCD LUCD LUCD LUCD
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2025-11-12 2025-08-12 2024-11-12 2024-08-12 2024-05-13 2023-11-13 2023-08-14 2023-05-15 2022-11-14
acceptedDate 2025-11-12 08:01:13 2025-08-12 17:29:09 2025-03-24 08:00:34 2024-11-12 16:36:53 2024-08-12 08:31:44 2024-05-13 08:21:56 2024-03-25 17:21:28 2023-11-13 17:15:24 2023-08-14 16:45:44 2023-05-15 16:25:34 2023-03-13 18:36:29 2022-11-14 16:08:08 2022-04-05 21:21:44 2020-12-31 00:00:00
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
revenue 1 211M 1M 4M 1M 976 000 1M 2M 783 000 159 000 446 000 377 000 76 000 500 000 0
costOfRevenue 1 697M 2M 8M 2M 2M 2M 8M 2M 2M 1M 4M 2M 585 000 0
grossProfit -486M -622 000 -4M -512 000 -867 000 -1M -6M -851 000 -1M -892 000 -3M -2M -85 000 0
grossProfitRatio -0.401 -0.535 -0.437 -0.888 -1.155 -1.087 -8.742 -2 -20.395
researchAndDevelopmentExpenses 1 272M 1M 6M 2M 1M 2M 7M 2M 2M 2M 11M 3M 9M 5M
generalAndAdministrativeExpenses 5 605M 5 617M 20 156M 5M 5M 4M 19M 4M 4M 7M 24M 6M 13M 3M
sellingAndMarketingExpenses 4 291M 4 007M 16 463M 4M 4M 4M 16M 4M 4M 4M 16M 4M 5M 0
sellingGeneralAndAdministrativeExpenses 9 896M 9 624M 36 619M 9M 9M 8M 36M 8M 8M 11M 40M 10M 18M 3M
otherExpenses 105M -9 614M -36 583M 0 0 372M -478 000 -3M 505M 505 000 2M 505 000 0 0
operatingExpenses 11 273M 11M 42M 11M 10M 10M 42M 10M 10M 13M 53M 13M 27M 8M
costAndExpenses 12 970M 13M 50M 13M 12M 12M 51M 12M 12M 15M 57M 14M 28M 8M
interestIncome 101M 110 000 322 000 81 000 107 000 68 000 424 000 116 000 136 000 78 000 88 000 0 0 0
interestExpense 2M 6000 26 000 1000 6000 12 000 416 000 149 000 223 000 33 000 8000 0 659 000 0
depreciationAndAmortization 441M 222 000 1M 215 000 229 000 501 000 2M 625 000 633 000 -1M 2M 593 000 4000 8M
ebitda -9 954M -4M -44M -12M -11M -10M -50M -13M -11M -16M -54M -14M -27M 482
ebitdaratio -8.22 -3.621 -10.371 -11.035 -10.281 -17.124 -68.019 -34.982 -181
operatingIncome -11 759M -11M -46M -12M -11M -11M -48M -11M -12M -14M -56M -14M -27M -8M
operatingIncomeRatio -9.71 -9.788 -9.978 -11.467 -10.781 -14.212 -72.855 -32.101 -188.803
totalOtherIncomeExpensesNet 1 362M 7M 523 000 -677 000 187 000 180 000 -4M -3M 290 000 -2M 0 0 -659 000 0
incomeBeforeTax -10 397M -4M -46M -12M -11M -11M -53M -14M -11M -16M -56M -14M -28M -8M
incomeBeforeTaxRatio -8.585 -3.817 -10.555 -11.276 -10.601 -18.146 -71.579 -36.428 -188.803
incomeTaxExpense 0 0 0 0 0 7 496M 0 -3M 223 000 1 963M 0 0 0 0
netIncome -10 397M -4M -46M -12M -11M -11M -53M -14M -11M -1 979M -56M -14M -28M -8M
netIncomeRatio -8.585 -3.817 -10.555 -11.276 -10.601 -18.146 -71.579 -4437.774 -188.803
eps -0.1 -0.08 -1.05 -0.25 -0.23 -0.24 -1.26 -0.34 -0.27 -48.31 -1.55 -0.39 -0.78 -0.22
epsdiluted -0.1 -0.08 -0.25 -0.23 -0.24 -0.34 -0.27 -48.31 -0.39
weightedAverageShsOut 108M 99M 51M 50M 48M 45M 42M 42M 42M 41M 36M 36M 36M 37M
weightedAverageShsOutDil 108M 99M 51M 50M 48M 45M 42M 42M 42M 41M 36M 36M 36M 37M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-03-24 2024-03-25 2023-03-14 2022-04-06 2020-12-31
fiscalYear 2024 2023 2022 2021 2020
netInterestIncome 296 000 8000 80 000 -659 000 0
ebit -46M -52M -56M -27M -8M
nonOperatingIncomeExcludingInterest -549 000 4M 0 0 0
netIncomeFromContinuingOperations -46M -53M -56M -28M -8M
netIncomeFromDiscontinuedOperations 0 0 0 0 0
otherAdjustmentsToNetIncome 0 0 0 0 0
netIncomeDeductions 0 0 0 0 0
bottomLineNetIncome -53M -53M -56M -28M -8M
epsDiluted -1.05 -1.26 -1.55 -0.78 -0.22

Balance Sheet Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol LUCD LUCD LUCD LUCD LUCD LUCD LUCD LUCD LUCD LUCD LUCD LUCD LUCD LUCD
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2025-11-12 2025-08-12 2024-11-12 2024-08-12 2024-05-13 2023-11-13 2023-08-14 2023-05-15 2022-11-14
acceptedDate 2025-11-12 08:01:13 2025-08-12 17:29:09 2025-03-24 08:00:34 2024-11-12 16:36:53 2024-08-12 08:31:44 2024-05-13 08:21:56 2024-03-25 17:21:28 2023-11-13 17:15:24 2023-08-14 16:45:44 2023-05-15 16:25:34 2023-03-13 18:36:29 2022-11-14 16:08:08 2022-04-05 21:21:44 2020-12-31 00:00:00
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
cashAndCashEquivalents 47M 31M 22M 14M 25M 25M 19M 24M 33M 40M 22M 27M 54M 111 000
shortTermInvestments 0 0 0 0 0 0 0 0 3M 0 0 0 0 0
cashAndShortTermInvestments 47M 31M 22M 14M 25M 25M 19M 24M 33M 40M 22M 27M 54M 111 000
netReceivables 550 000 373 000 405 000 39 000 160 000 49 000 45 000 21 000 35 000 27 000 17 000 31 000 200 000 0
inventory 856 000 981 000 341 000 651 000 683 000 638 000 278 000 190 000 42 000 62 000 111 000 104 000 493 000 834 000
otherCurrentAssets 1M 1M 0 2M 2M 2M 2M 3 232M 3 144M 2 172M 0 3M 0 0
totalCurrentAssets 50M 34M 25M 17M 28M 28M 22M 27M 36M 42M 24M 30M 57M 1M
propertyPlantEquipmentNet 3M 3M 4M 4M 4M 2M 3M 3M 3M 3M 4M 4M 971 000 0
goodwill 0 0 0 0 0 0 0 0 0 0 0 0 0 0
intangibleAssets 421 000 526 000 736 000 842 000 947 000 1M 1M 2M 2M 3M 3M 4M 0 0
goodwillAndIntangibleAssets 421 000 526 000 736 000 842 000 947 000 1M 1M 2M 2M 3M 3M 4M 0 0
longTermInvestments 0 0 0 0 0 0 0 0 0 0 0 0 0 0
taxAssets 0 0 0 0 0 0 0 0 0 0 0 0 0 0
otherNonCurrentAssets 52 000 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 725 000 755 000
totalNonCurrentAssets 3M 5M 6M 6M 6M 4M 5M 6M 7M 7M 8M 9M 2M 755 000
otherAssets 0 0 0 1 0 0 0 0 0 0 0 0 0 0
totalAssets 53M 39M 31M 23M 34M 32M 27M 33M 42M 49M 33M 38M 59M 2M
accountPayables 751 000 833 000 1M 1M 903 000 969 000 1M 994 000 637 000 625 000 1M 1M 1M 2M
shortTermDebt 23M 26M 19M 11M 12M 14M 14M 16M 13M 13M 0 860 000 0 0
taxPayables 0 0 0 0 0 0 0 0 0 0 0 0 0 0
deferredRevenue 0 0 0 0 0 0 936 000 -13 598M -13 324M 0 0 0 0 0
otherCurrentLiabilities 2M 2M 1M 2M 3M 5M 791 000 13 612M 13 337M 10M 6M 8M 557 000 0
totalCurrentLiabilities 26M 29M 24M 14M 16M 20M 29M 30M 27M 23M 8M 10M 4M 16M
longTermDebt 1M 1M 0 2M 2M 177 000 0 464 000 732 000 826 000 0 1M 0 0
deferredRevenueNonCurrent 0 0 0 0 0 0 0 0 0 0 0 0 0 0
deferredTaxLiabilitiesNonCurrent 0 0 0 0 0 0 0 0 0 0 0 0 0 0
otherNonCurrentLiabilities 0 0 0 0 0 -1 0 0 0 0 0 -819 000 0 0
totalNonCurrentLiabilities 1M 1M 2M 2M 2M 176 999 199 000 464 000 732 000 826 000 1M 1M 0 0
otherLiabilities 0 0 0 0 0 1 0 0 0 0 0 0 0 0
capitalLeaseObligations 1M 2M 3M 3M 3M 177 000 1M 2M 2M 2M 2M 2M 0 0
totalLiabilities 27M 31M 25M 16M 18M 20M 30M 31M 27M 24M 9M 11M 4M 16M
preferredStock 54M 54M 54M 56M 56M 44M 19M 14M 14M 14M 0 0 0 0
commonStock 131 000 102 000 63 000 52 000 49 000 47 000 42 000 42 000 42 000 42 000 41 000 37 000 35 000 14 000
retainedEarnings -258M -248M -204M -192M -180M -169M -151M -140M -126M -114M -98M -83M -42M -14M
accumulatedOtherComprehensiveIncomeLoss 0 0 0 0 0 -47 000 0 -13 625M -13 625M 0 0 0 0 0
othertotalStockholdersEquity 229M 201M 143M 140M 136M 13 754M 13 752M 126M 111M
totalStockholdersEquity 26M 8M 5M 6M 16M 12M -2M 3M 15M 25M 23M 28M 55M -14M
totalEquity 26M 8M 5M 6M 16M 12M -2M 3M 15M 25M 23M 28M 55M -14M
totalLiabilitiesAndStockholdersEquity 53M 39M 23M 34M 32M 33M 42M 49M 38M
minorityInterest 0 0 0 0 0 0 0 0 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 53M 39M 31M 23M 34M 32M 27M 33M 42M 49M 33M 38M 59M 2M
totalInvestments 0 0 0 -14 475M 0 0 0 0 3M 0 0 0 0 0
totalDebt 24M 28M 21M 13M 14M 14M 15M 16M 13M 14M 2M 2M 0 0
netDebt -23M -4M -1M -1M -11M -11M -4M -8M -19M -26M -20M -25M -54M -111 000
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-03-24 2024-03-25 2023-03-14 2022-04-06 2020-12-31
fiscalYear 2024 2023 2022 2021 2020
accountsReceivables 45 000 45 000 17 000 200 000 0
otherReceivables 360 000 0 0 0 0
prepaids 2M 873 000 2M 3M 495 000
totalPayables 1M 10M 1M 3M 15M
otherPayables 0 9M 0 2M 13M
accruedExpenses 1M 2M 879 000 556 000 394 000
capitalLeaseObligationsCurrent 854 000 1M 962 000 0 0
capitalLeaseObligationsNonCurrent 2M 199 000 1M 0 0
treasuryStock 0 0 0 0 0
additionalPaidInCapital 155M 130M 121M 97M 294 000
otherTotalStockholdersEquity 0 0 0 0 0

Cash Flow Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol LUCD LUCD LUCD LUCD LUCD LUCD LUCD LUCD LUCD LUCD LUCD LUCD LUCD LUCD
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2025-11-12 2025-08-12 2024-11-12 2024-08-12 2024-05-13 2023-11-13 2023-08-14 2023-05-15 2022-11-14
acceptedDate 2025-11-12 08:01:13 2025-08-12 17:29:09 2025-03-24 08:00:34 2024-11-12 16:36:53 2024-08-12 08:31:44 2024-05-13 08:21:56 2024-03-25 17:21:28 2023-11-13 17:15:24 2023-08-14 16:45:44 2023-05-15 16:25:34 2023-03-13 18:36:29 2022-11-14 16:08:08 2022-04-05 21:21:44 2020-12-31 00:00:00
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
netIncome -10M -4M -46M -12M -11M -11M -53M -14M -11M -16M -56M -14M -28M -8M
depreciationAndAmortization 220 000 222 000 1M 215 000 229 000 501 000 2M 625 000 633 000 612 000 2M 593 000 4000 0
deferredIncomeTax 0 0 0 0 0 0 0 4M -1M 0 0 0 0 0
stockBasedCompensation 1M 1M 5M 1M 1M 932 000 7M 1M 1M 3M 15M 4M 10M 65 000
changeInWorkingCapital -692 000 -709 000 -4M -139 000 -2M -3M 6M 503 000 3M 3M 9M 4M 807 000 3M
accountsReceivables -177 000 -312 000 0 122 000 -111 000 -4000 -28 000 14 000 -8000 -10000 183 000 -31 000 -200 000 0
inventory 0 0 0 0 0 0 0 0 0 0 0 0 0 0
accountsPayables -82 000 4000 96 000 233 000 -67 000 -176 000 89 000 357 000 12 000 -431 000 -445 000 -1M -665 000 1M
otherWorkingCapital -433 000 -401 000 -5M -494 000 -2M -3M 6M 132 000 3M 3M 9M 5M 2M 1M
otherNonCashItems -1M -7M 119 000 892 000 5000 2M 5M -1M 1M 3M 653 000 188 000 0 459
netCashProvidedByOperatingActivities -11M -11M -44M -10M -11M -13M -33M -9M -7M -7M -30M -6M -18M -6M
investmentsInPropertyPlantAndEquipment -28 000 -25 000 -296 000 37 000 0 -37 000 -221 000 -14 000 -15 000 -17 000 -908 000 -321 000 -862 000 0
acquisitionsNet 0 0 0 0 0 0 0 0 0 0 0 -1 000 000 0 0
purchasesOfInvestments 0 0 0 0 0 0 0 0 0 0 0 0 0 0
salesMaturitiesOfInvestments 0 0 0 0 0 0 0 0 0 0 0 0 0 0
otherInvestingActivites 0 0 -387M 0 -37M 0 0 0 0
netCashUsedForInvestingActivites -28 000 -25 000 -387M 0 -37 000 -14 000 -15 000 -17 000 -1M
debtRepayment 0 0 0 0 0 0 0 0 0
commonStockIssued 27M 16M 29 768M 12M 19M 275 000 75 000 284 000 0
commonStockRepurchased 0 0 0 94M 0 353M 0 0 0 276M 0 0 0 0
dividendsPaid 0 0 0 0 0 0 0 0 0
otherFinancingActivites 0 10000 94 000 12M 4M 0 0 -252M 2M
netCashUsedProvidedByFinancingActivities 27M 16M 94 000 12M 19M 275 000 75 000 24M 2M
effectOfForexChangesOnCash 0 0 0 0 0 0 0 1 261M 1 406M 0 0 0 -255 0
netChangeInCash 16M 6M 3M -10M 151 000 6M -4M -9M -7M 17M -31M -6M 54M -45 149
cashAtEndOfPeriod 47M 31M 22M 14M 25M 25M 19M 24M 33M 40M 22M 27M 54M 111 255
cashAtBeginningOfPeriod 31M 25M 19M 25M 25M 19M 22M 33M 40M 22M 54M 33M 111 255 156 404
operatingCashFlow -11M -11M -44M -10M -11M -13M -33M -9M -7M -7M -30M -6M -18M -6M
capitalExpenditure -28 000 -25 000 -646 000 -350 000 0 -37 000 -221 000 -14 000 -15 000 -17 000 -908 000 -321 000 -862 000 0
freeCashFlow -11M -11M -45M -11M -11M -13M -33M -9M -7M -7M -31M -7M -19M -6M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-03-24 2024-03-25 2023-03-14 2022-04-06 2020-12-31
fiscalYear 2024 2023 2022 2021 2020
otherInvestingActivities -350 000 0 -3M 0 0
netCashProvidedByInvestingActivities -646 000 -221 000 -4M -862 000 0
netDebtIssuance 18M 10M 0 0 0
longTermNetDebtIssuance 0 10M 0 0 0
shortTermNetDebtIssuance 18M 0 0 0 0
netStockIssuance 30M 19M 2M 78M 6M
netCommonStockIssuance 0 284 000 2M 78M 6M
commonStockIssuance 0 284 000 2M 78M 6M
netPreferredStockIssuance 30M 19M 0 0 0
netDividendsPaid 0 0 0 0 0
commonDividendsPaid 0 0 0 0 0
preferredDividendsPaid 0 0 0 0 0
otherFinancingActivities 451 000 551 000 804 000 -6M 0
netCashProvidedByFinancingActivities 48M 29M 3M 72M 6M
incomeTaxesPaid 0 0 0 0 0
interestPaid 0 0 0 0 0

Earning call transcript

2025 q3
2025-11-12 ET (fiscal 2025 q3)
2025 q2
2025-08-13 ET (fiscal 2025 q2)
2024 q4
2025-03-24 ET (fiscal 2024 q4)
2024 q3
2024-05-13 ET (fiscal 2024 q3)
2024 q2
2024-08-12 ET (fiscal 2024 q2)
2024 q1
2024-05-13 ET (fiscal 2024 q1)
2023 q4
2024-03-26 ET (fiscal 2023 q4)
2023 q3
2023-11-14 ET (fiscal 2023 q3)
2023 q2
2023-08-15 ET (fiscal 2023 q2)
2023 q1
2023-05-16 ET (fiscal 2023 q1)
2022 q4
2023-03-14 ET (fiscal 2022 q4)
2022 q3
2022-11-14 ET (fiscal 2022 q3)
2022 q2
2022-08-15 ET (fiscal 2022 q2)
2022 q1
2022-05-11 ET (fiscal 2022 q1)

Press-releases

Show financial reports only

2026-08-14 ET
PAVmed Provides Business Update and Reports Second Quarter 2026 Financial Results
2026-08-13 ET
Lucid Diagnostics Provides Business Update and Reports Second Quarter 2026 Financial Results
2026-08-05 ET
Lucid Diagnostics Secures Commercial Coverage Policy Spanning Multiple Health Plans for its EsoGuard® Esophageal DNA Test
2026-08-04 ET
Lucid Diagnostics to Participate in Upcoming Investor Conferences
2026-07-31 ET
PAVmed to Hold Second Quarter 2026 Business Update Conference Call and Webcast on August 14, 2026
2026-07-30 ET
Lucid Diagnostics to Hold Second Quarter 2026 Business Update Conference Call and Webcast on August 13, 2026
2026-05-15 12:00 ET
PAVmed Provides Business Update and Reports First Quarter 2026 Financial Results
2026-05-14 12:00 ET
Lucid Diagnostics Provides Business Update and Reports First Quarter 2026 Financial Results
2026-05-01 12:31 ET
PAVmed to Hold First Quarter 2026 Business Update Conference Call and Webcast on May 15, 2026
2026-04-30 12:31 ET
Lucid Diagnostics to Hold First Quarter 2026 Business Update Conference Call and Webcast on May 14, 2026
2026-04-23 12:30 ET
Lucid Diagnostics Announces $18 Million Underwritten Offering of Common Stock
2026-04-09 ET
Lucid Diagnostics to Participate in Fireside Chat at the 25th Annual Needham Virtual Healthcare Conference
2026-04-02 ET
PAVmed Appoints Joseph Virgilio to Lead Relaunched Medical Device Portfolio
2026-03-30 ET
PAVmed Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results
2026-03-12 ET
Lucid Diagnostics to Hold Fourth Quarter and Full Year 2025 Business Update Conference Call and Webcast on March 26, 2026
2026-02-04 ET
PAVmed Closes Preferred Stock and Senior Secured Note Financings, Eliminating All Previously Outstanding Convertible Securities
2026-01-21 ET
Lucid Diagnostics Awarded U.S. Department of Veterans Affairs Contract for EsoGuard®
2025-12-30 ET
PAVmed Announces Reverse Stock Split
2025-12-09 13:01 ET
Lucid Diagnostics Announces Positive Data from the Largest Reported Real-World Experience of Esophageal Precancer Detection
2025-11-20 13:15 ET
Lucid Diagnostics Named a GenomeWeb 2025 Best Places to Work Top-Ranking Honoree
2025-11-13 13:15 ET
Lucid Diagnostics to Participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum
2025-11-13 13:00 ET
PAVmed Provides Business Update and Reports Third Quarter 2025 Financial Results
2025-11-12 13:00 ET
Lucid Diagnostics Provides Business Update and Reports Third Quarter 2025 Financial Results
2025-10-29 12:01 ET
Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on November 12, 2025
2025-10-15 12:01 ET
Lucid Diagnostics to Participate in the 2025 Maxim Growth Summit
2025-09-25 12:01 ET
Lucid Diagnostics Appoints Healthcare Industry Veteran John R. Palumbo to Board of Directors
2025-09-16 ET
Lucid Diagnostics Appoints Danielle Scelfo as Senior Vice President, Market Access & Government Affairs
2025-09-11 ET
Lucid Diagnostics Announces Closing of Public Offering of Common Stock
2025-09-10 ET
Lucid Diagnostics Announces Pricing of Public Offering of Common Stock
2025-09-09 ET
Lucid Diagnostics Announces Proposed Public Offering of Common Stock
2025-09-05 ET
Lucid Diagnostics to Host Investor Call on Monday, September 8, 2025
2025-08-27 ET
Lucid Diagnostics to Participate in the Cantor Global Healthcare Conference 2025
2025-08-26 ET
PAVmed Signs Letter of Intent to License Groundbreaking Endoscopic Esophageal Imaging Technology
2025-08-14 ET
PAVmed Provides Business Update and Reports Second Quarter 2025 Financial Results
2025-08-13 ET
Lucid Diagnostics Provides Business Update and Reports Second Quarter 2025 Financial Results
2025-08-05 ET
Lucid Diagnostics to Participate in Upcoming Investor Conferences
2025-07-30 ET
Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on August 13, 2025
2025-07-16 ET
MolDX to Convene Expert Medical Panel on Medicare Local Coverage Determination (LCD) for Lucid Diagnostics' EsoGuard® Esophageal DNA Test
2025-06-18 ET
Major California Health System Launches Comprehensive Esophageal Precancer Testing Program Using Lucid Diagnostics' EsoGuard® Esophageal DNA Test
2025-05-27 11:31 ET
Lucid Diagnostics to Join Russell 2000® and Russell 3000® Indexes
2025-05-15 ET
PAVmed Provides Business Update and Reports First Quarter 2025 Financial Results
2025-05-14 ET
Lucid Diagnostics Provides Business Update and Reports First Quarter 2025 Financial Results
2025-05-01 ET
PAVmed to Hold a Business Update Conference Call and Webcast on May 15, 2025
2025-04-30 ET
Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on May 14, 2025
2025-04-24 ET
NCI-Sponsored Study Shows Positive Data for Lucid Diagnostics' EsoGuard® Esophageal DNA Test in Patients Without Symptomatic GERD
2025-04-11 ET
Lucid Diagnostics Announces Closing of Public Offering of Common Stock
2025-04-09 ET
Lucid Diagnostics Announces Pricing of Public Offering of Common Stock
2025-04-09 ET
Lucid Diagnostics Announces Proposed Public Offering of Common Stock
2025-04-03 ET
Lucid Diagnostics to Participate in Fireside Chat at the 24th Annual Needham Virtual Healthcare Conference
2025-03-27 ET
Lucid Diagnostics Launches "Embrace the Future" Campaign Showcasing EsoCheck's Groundbreaking Collect+Protect Esophageal Cell Collection Technology
2025-03-25 ET
PAVmed Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results
2025-03-24 ET
Lucid Diagnostics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results
2025-03-20 ET
Lucid Diagnostics Announces Updated National Comprehensive Cancer Network® (NCCN) Guidelines Now Include Esophageal Precancer Screening
2025-03-18 ET
Lucid Diagnostics' ENVET-BE Clinical Utility Study of EsoGuard® Esophageal Precancer Testing Accepted for Peer-Reviewed Publication
2025-03-13 ET
Lucid Diagnostics Secures First Positive Commercial Insurance Coverage Policy for its EsoGuard® Esophageal DNA Test
2025-03-10 ET
Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on March 24, 2025
2025-03-04 ET
Lucid Diagnostics Announces $15.3 Million Registered Direct Offering
2025-02-27 ET
Renowned Investigators Awarded $8 Million NIH Grant to Study Lucid Diagnostics' EsoGuard® in At-Risk Patients without Symptomatic GERD
2025-02-25 ET
Lucid Diagnostics Regains Compliance with Nasdaq Minimum Bid Price Requirement
2025-02-20 ET
Lucid Diagnostics Executes First Concierge Medicine Contract with LEAA Health
2025-02-18 ET
PAVmed Regains Compliance with Nasdaq Stockholders' Equity Requirement
2025-02-06 ET
Lucid Diagnostics to Participate in the 12th Annual BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
2025-01-13 ET
Lucid Diagnostics Announces Record Quarterly EsoGuard® Test Volume
2024-12-23 ET
Lucid Diagnostics Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule
2024-12-19 ET
Lucid Diagnostics Partners with VITALExam to Enhance Esophageal Precancer Detection for Firefighters
2024-12-11 ET
Prospective Clinical Utility Study of Lucid Diagnostics' EsoGuard® Esophageal DNA Test Accepted for Peer-Reviewed Publication
2024-12-03 ET
Lucid Diagnostics Completes Convertible Debt Refinancing to Strengthen Balance Sheet and Extend Cash Runway Past Key Near-Term Milestones
2024-11-20 ET
Lucid Diagnostics Submits Clinical Evidence Package to MolDX Seeking Medicare Coverage for EsoGuard® Esophageal DNA Test
2024-11-18 ET
Lucid Diagnostics to Present at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum
2024-11-14 13:01 ET
PAVmed Provides Business Update and Third Quarter 2024 Financial Results
2024-11-13 13:01 ET
Lucid Diagnostics Provides Business Update and Third Quarter 2024 Financial Results
2024-11-07 13:01 ET
Lucid Diagnostics' ESOGUARD BE-1 Prospective Multicenter Clinical Validation Study of EsoGuard® Esophageal Precancer Testing Accepted for Peer-Reviewed Publication
2024-11-05 13:01 ET
Lucid Diagnostics Expands Direct Contracting Initiative with Multiple Programs Focused on Near-Term Revenue Drivers
2024-10-31 12:31 ET
PAVmed to Hold a Business Update Conference Call and Webcast on November 14, 2024
2024-10-30 12:31 ET
Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on November 13, 2024
2024-10-15 11:51 ET
Lucid Diagnostics Receives Notice of Allowance for Key Patent Underlying Its EsoGuard Esophageal DNA Test
2024-10-09 12:01 ET
Lucid Diagnostics to Participate in the 2024 Maxim Healthcare Virtual Summit
2024-10-08 11:49 ET
Lucid Diagnostics to Join Global Medtech Leaders at The MedTech Conference 2024
2024-10-01 12:01 ET
Lucid Diagnostics Holds Inaugural #CheckYourFoodTube Precancer Testing Event for Former NFL Players
2024-09-24 12:01 ET
American Foregut Society's 2024 Annual Meeting to Highlight Lucid Diagnostics' EsoGuard Esophageal Precancer Test
2024-09-16 20:30 ET
PAVmed Announces Efforts to Regain Compliance with Nasdaq Listing Requirements
2024-09-10 11:56 ET
Lucid Diagnostics to Host Symposium on Non-Endoscopic Esophageal Precancer Screening at the 20th International Society for Diseases of the Esophagus (ISDE) World Congress
2024-09-03 11:51 ET
Lucid Diagnostics Signs Memorandum of Understanding with Front Line Mobile Health
2024-08-20 12:16 ET
Lucid Diagnostics Announces Publication of Analytical Validation Study of EsoGuard® for Early Detection of Esophageal Precancer and Cancer
2024-08-13 12:16 ET
The American Foregut Society Formally Requests Medical Policy Coverage of EsoGuard® to Enhance Early Detection of Esophageal Cancer
2024-08-13 12:01 ET
PAVmed Provides Business Update and Second Quarter 2024 Financial Results
2024-08-12 12:07 ET
Lucid Diagnostics Provides Business Update and Second Quarter 2024 Financial Results
2024-08-08 12:31 ET
Lucid Diagnostics Holds First Major Directly-Contracted EsoGuard® #CheckYourFoodTube Precancer Testing Event
2024-08-06 12:15 ET
Lucid Diagnostics Announces Positive Data from ENVET-BE Clinical Utility Study of EsoGuard® Esophageal Precancer Testing
2024-08-05 12:15 ET
Lucid Diagnostics to Participate in Upcoming Investor Conferences
2024-07-30 12:15 ET
PAVmed to Hold a Business Update Conference Call and Webcast on August 13, 2024
2024-07-29 12:15 ET
Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on August 12, 2024
2024-07-23 12:01 ET
Lucid Diagnostics Announces Record Quarterly EsoGuard® Test Volume
2024-07-11 12:31 ET
Lucid Diagnostics Launches New Corporate Website
2024-07-02 11:55 ET
Lucid Diagnostics Announces Positive Data from its ESOGUARD BE-1 Prospective, International, Multicenter Clinical Validation Study of EsoGuard® Esophageal Precancer Testing in a Screening Population
2024-06-12 12:05 ET
4,000th Firefighter Undergoes Lucid Diagnostics' EsoGuard® Esophageal Precancer Testing
2024-05-14 00:43 ET
PAVmed Provides Business Update and First Quarter 2024 Financial Results
2024-05-13 12:00 ET
Lucid Diagnostics Provides Business Update and First Quarter 2024 Financial Results
2024-05-09 11:49 ET
Legacy Sponge-on-a-String Esophageal Cell Collection Device Subject of Class II FDA Recall
2024-05-07 11:39 ET
Lucid Diagnostics Closes Series B / B-1 Preferred Stock Offering and Appoints Healthcare Industry Veteran Dennis Matheis to Board of Directors
2024-05-02 12:35 ET
Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on May 13, 2024
2024-05-02 11:49 ET
Lucid Diagnostics Announces Peer-Reviewed Publication of Positive Data from National Cancer Institute-Sponsored, Prospective, Multicenter Clinical Validation Study of EsoGuard® Esophageal Precancer Testing
2024-04-29 12:47 ET
Lucid Diagnostics Partners with the Esophageal Cancer Action Network (ECAN) to Highlight Esophageal Cancer Awareness Month
2024-04-08 12:30 ET
Lucid Diagnostics to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference
2024-03-26 23:32 ET
PAVmed Provides Business Update and Fourth Quarter and Full Year 2023 Financial Results
2024-03-25 21:30 ET
Lucid Diagnostics Provides Business Update and Preliminary Fourth Quarter and Full Year 2023 Financial Results
2024-03-21 13:30 ET
Lucid Diagnostics Announces Positive Data from the First Prospective Clinical Validation Study of EsoGuard® Esophageal Precancer Testing in a Screening Population
2024-03-20 12:30 ET
Lucid Diagnostics Announces Multiple Presentations at the Upcoming Digestive Disease Week (DDW) 2024 Conference
2024-03-12 12:30 ET
Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on March 26, 2024
2024-02-16 22:00 ET
Lucid Diagnostics Provides Update Regarding World Trade Center Health Program
2024-02-15 12:45 ET
Lucid Diagnostics Chairman & CEO, Dr. Lishan Aklog, Highlights EsoCheck® Esophageal Cell Collection Device during Congressional Testimony
2024-02-08 12:45 ET
Lucid Diagnostics Executes Contract to Provide EsoGuard® Esophageal Precancer Testing as a Covered Benefit for 9/11 Responders and Survivors
2023-12-12 13:30 ET
Lucid Diagnostics Announces Peer-Reviewed Publication of Positive Results from Three Clinical Utility Studies
2023-12-11 14:00 ET
PAVmed Provides Additional Details for Upcoming Stock Dividend to Shareholders
2023-12-04 21:20 ET
PAVmed Announces Dividend of Lucid Diagnostics Common Stock and Reverse Stock Split
2023-11-16 14:00 ET
Lucid Diagnostics Strengthens and Expands Market Access and Direct Contracting Efforts
2023-11-14 22:43 ET
PAVmed Provides Business Update and Third Quarter Financial Results
2023-11-13 22:40 ET
Lucid Diagnostics Provides Business Update and Third Quarter Financial Results
2023-11-09 14:00 ET
Lucid Diagnostics Launches Next-Generation EsoGuard® Esophageal DNA Test and Announces Upcoming Investor Day
2023-11-02 13:18 ET
Lucid Diagnostics to Present at Canaccord Genuity Medtech, Diagnostics, and Digital Health & Services Forum
2023-11-01 13:10 ET
PAVmed to Hold a Business Update Conference Call and Webcast on November 15, 2023
2023-10-31 13:00 ET
Lucid Diagnostics Announces PREVENT and PREVENT-FF Registries of EsoGuard® Esophageal Precancer Detection
2023-10-31 12:55 ET
Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on November 14, 2023
2023-09-21 12:30 ET
PAVmed and Lucid Diagnostics to Participate in Panel Presentation at the 2023 Cantor Fitzgerald Global Healthcare Conference
2023-09-07 13:26 ET
Lucid Diagnostics Releases Positive Data from First Prospective Clinical Utility Study of EsoGuard® Esophageal Precancer Detection
2023-09-06 13:00 ET
Lucid Diagnostics Releases Positive Data Demonstrating Clinical Utility of EsoGuard® Esophageal Precancer Detection in Fire Fighters
2023-08-24 13:00 ET
Lucid Diagnostics Executes First Direct Employer Contract to Provide EsoGuard® Esophageal Precancer Testing as an Employee Benefit
2023-08-16 00:17 ET
PAVmed Provides Business Update and Second Quarter Financial Results
2023-08-14 22:48 ET
Lucid Diagnostics Provides Business Update and Second Quarter Financial Results
2023-07-31 22:19 ET
PAVmed to Hold a Business Update Conference Call and Webcast on August 16, 2023
2023-07-31 22:00 ET
Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on August 15, 2023
2023-07-26 12:30 ET
Lucid Diagnostics to Present at the Canaccord Genuity 43rd Annual Growth Conference
2023-07-19 13:04 ET
PAVmed and Lucid Chairman and Chief Executive Officer, Dr. Lishan Aklog, Testifies at U.S. House of Representatives Energy and Commerce Committee, Hearing on Life-Saving Innovations and Medicare Coverage
2023-06-28 20:05 ET
PAVmed Receives 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Price Requirement
2023-06-14 20:05 ET
PAVmed to Participate in Healthcare Virtual Conference Presented by Maxim Group LLC
2023-06-05 11:00 ET
Lucid Diagnostics Launches First EsoGuard® Mobile Test Unit
2023-06-02 11:00 ET
PAVmed Digital Health Subsidiary, Veris Health, Joins Cancer Moonshot's CancerX Partnership as Founding Member
2023-05-16 21:00 ET
PAVmed Provides Business Update and First Quarter Financial Results
2023-05-15 22:21 ET
Lucid Diagnostics Provides Business Update and First Quarter Financial Results
2023-05-11 12:45 ET
Lucid Diagnostics and Collaborators Present New EsoGuard® and EsoCheck® Data at Digestive Disease Week® (DDW) 2023 Conference
2023-05-05 13:00 ET
Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on May 16, 2023
2023-05-05 13:00 ET
PAVmed to Hold a Business Update Conference Call and Webcast on May 17, 2023
2023-04-25 12:45 ET
PAVmed Digital Health Subsidiary, Veris Health, Appoints Gary Manning as President
2023-04-19 12:45 ET
PAVmed Digital Health Subsidiary, Veris Health, to Present Comprehensive Meta-analysis on Impact of Remote Patient Monitoring in Oncology at HIMSS
2023-04-18 12:45 ET
Lucid Diagnostics Reports Publication of Future Effective Foundational Local Coverage Determination by Medicare Administrative Contractor Noridian Healthcare Solutions
2023-04-18 01:45 ET
Lucid Diagnostics to Present at 22nd Annual Needham Virtual Healthcare Conference
2023-03-31 16:45 ET
Lucid Diagnostics Provides Update on Newly Published Future Effective Medicare Local Coverage Determination on Molecular Testing for Detection of Esophageal Precancer and Cancer
2023-03-14 23:09 ET
PAVmed Provides Business Update and Preliminary Fourth Quarter and Full Year 2022 Financial Results
2023-03-13 22:21 ET
/C O R R E C T I O N -- Lucid Diagnostics/
2023-03-03 13:15 ET
Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on March 14, 2023
2023-03-03 13:15 ET
PAVmed to Hold a Business Update Conference Call and Webcast on March 15, 2023
2023-02-28 13:30 ET
PAVmed Digital Health Subsidiary Veris Health's Veris Cancer Care Platform™ Goes Live
2023-02-15 13:30 ET
Lucid Diagnostics Holds First #CheckYourFoodTube Precancer Testing Event
2023-01-17 21:05 ET
PAVmed and Lucid Diagnostics Provide Strategic Business Update
2023-01-11 13:00 ET
PAVmed and Lucid Diagnostics to Provide Strategic Business Update
2022-12-22 13:25 ET
PAVmed Partners with Novosound on Ultrasound Imaging Technology
2022-12-15 13:25 ET
PAVmed Digital Health Subsidiary Veris Health Launches Veris Cancer Care Platform
2022-12-08 13:25 ET
Lucid Diagnostics Selected as Finalist for Medtech Company of the Year 2022 by Medical Device + Diagnostic Industry
2022-12-01 13:25 ET
Lucid Diagnostics Presents Real-World EsoCheck Data at the American Association for Cancer Research
2022-11-15 21:20 ET
PAVmed Provides Business Update and Third Quarter 2022 Financial Results
2022-11-14 21:40 ET
Lucid Diagnostics Provides Business Update and Third Quarter 2022 Financial Results
2022-11-10 13:25 ET
Lucid Diagnostics to Participate in Canaccord Genuity’s MedTech, Diagnostics and Digital Health & Services Forum
2022-11-09 13:25 ET
Lucid Diagnostics Commences Production of EsoCheck Devices with High-Volume Manufacturer
2022-11-02 12:25 ET
Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on November 14, 2022
2022-08-15 20:25 ET
Lucid Diagnostics Provides Business Update and Preliminary Second Quarter 2022 Financial Results
2022-08-11 12:25 ET
Lucid Diagnostics Launches Stage II Lucid Test Center Expansion in California, Texas, Florida, and Ohio
2022-08-04 12:25 ET
Newly Published American Gastroenterological Association Clinical Practice Update Supports Esophageal Precancer Screening Using Lucid Diagnostics’ EsoGuard® and EsoCheck® Technologies
2022-08-02 12:25 ET
Lucid Diagnostics’ Laboratory Executes Four New Participating Provider Agreements
2022-08-01 12:25 ET
Lucid Diagnostics to Hold a Business Update Conference Call on August 15, 2022
2022-07-18 12:25 ET
Lucid Diagnostics to Participate in the Canaccord 42nd Annual Growth Conference and the 7th Annual Needham Med Tech & Diagnostics 1x1 Conference
2022-05-13 12:25 ET
PAVmed and Lucid Diagnostics Chairman & CEO Lishan Aklog, M.D. Named Top 50 Healthcare Technology CEO
2022-05-11 20:00 ET
Lucid Diagnostics Provides Business Update and Preliminary First Quarter 2022 Financial Results
2022-05-09 12:25 ET
Lucid Diagnostics’ Laboratory Executes Participating Provider Agreement with MediNcrease Health Plans
2022-05-04 11:03 ET
Lucid Diagnostics Selects Veeva Vault CDMS for EsoGuard® Study
2022-04-26 12:25 ET
PAVmed to Hold a Business Update Conference Call on May 12, 2022
2022-04-25 12:25 ET
Lucid Diagnostics to Hold a Business Update Conference Call on May 11, 2022
2022-04-04 12:25 ET
Lucid Diagnostics Provides Updates on Newly Published Esophageal Precancer Clinical Guideline and Proposed Medicare Local Coverage Determination
2022-03-30 12:25 ET
Lucid Diagnostics to Participate in the Needham 21st Annual Healthcare Conference
2022-03-29 20:11 ET
PAVmed Provides Business Update and Preliminary Fourth Quarter and Full Year 2021 Financial Results
2022-03-28 20:47 ET
Lucid Diagnostics Provides Business Update and Preliminary Fourth Quarter and Full Year 2021 Financial Results
2022-03-24 12:25 ET
PAVmed Subsidiary Lucid Diagnostics Announces Launch of VA EsoGuard® Study
2022-03-23 12:25 ET
PAVmed Subsidiary Lucid Diagnostics Launches Next Phase of Lucid Test Centers
2022-03-17 12:25 ET
PAVmed Announces Successful First-in-Human Implantations of its PortIO™ Intraosseous Infusion System
2022-03-08 13:30 ET
PAVmed to Hold a Business Update Conference Call on March 29, 2022
2022-03-07 13:30 ET
Lucid Diagnostics to Hold a Business Update Conference Call on March 28, 2022
2022-03-04 13:25 ET
Lucid Diagnostics to Participate in the LSI USA ’22 Emerging Medtech Summit
2022-03-03 13:25 ET
PAVmed Subsidiary Lucid Diagnostics Launches LucidDx Labs to Accommodate EsoGuard Testing Growth
2022-02-24 13:25 ET
PAVmed Appoints Shaun O’Neil as Chief Operating Officer
2022-02-15 13:25 ET
Evernorth Executive and Healthcare Services Industry Leader Joan Harvey Named to PAVmed Board of Directors
2022-02-10 13:25 ET
Lucid Diagnostics to Participate in a Fireside Chat at the BTIG MedTech Digital Health, Life Science, and Diagnostics Tools Conference
2022-01-12 13:25 ET
PAVmed and Lucid Diagnostics Welcome New Full-Time Investor Relations Team
2022-01-06 13:30 ET
Lucid Diagnostics to Participate in a Fireside Chat at the 24th Annual Needham Virtual Growth Conference
2021-12-01 13:30 ET
PAVmed Subsidiary Lucid Diagnostics Launches EsoGuard Telemedicine Program in Partnership with UpScriptHealth
2021-11-17 13:30 ET
Lucid Diagnostics to Present at Canaccord Genuity Virtual MedTech, Diagnostics and Digital Health & Services Forum
2021-11-16 21:13 ET
PAVmed and Lucid Provide Business Update and Preliminary Third Quarter 2021 Financial Results
2021-11-11 13:30 ET
PAVmed Subsidiary Lucid Diagnostics Launches Next Phase of Lucid Test Centers
2021-11-03 12:30 ET
PAVmed and Lucid to Hold Joint Business Update Conference Call on November 16, 2021
2021-10-28 12:30 ET
Lucid Diagnostics’ EsoGuard Esophageal DNA Test Wins “Diagnostics Innovation of the Year” Award
2021-10-21 12:30 ET
ADDING MULTIMEDIA Lucid Diagnostics Appoints Suman Verma MD, PhD as Chief Scientific Officer
2021-10-18 22:09 ET
Lucid Diagnostics Announces Closing of Nasdaq Initial Public Offering
2021-10-18 21:45 ET
Lucid Diagnostics Announces Closing of Nasdaq Initial Public Offering
2021-10-14 02:15 ET
Lucid Diagnostics Announces Pricing of Initial Public Offering
2021-10-14 01:28 ET
Lucid Diagnostics Announces Pricing of Initial Public Offering

SEC forms

Show financial reports only

SEC form 8
2026-09-22 13:06 ET
Lucid Diagnostics Inc. published news for 2026 q2
SEC form 8
2026-09-22 13:06 ET
Lucid Diagnostics Inc. published news for 2026 q2
SEC form 8
2026-08-13 12:23 ET
Lucid Diagnostics Inc. published news for 2026 q2
SEC form 8
2026-08-13 12:23 ET
Lucid Diagnostics Inc. published news for 2026 q2
SEC form 10
2026-08-12 20:30 ET
Lucid Diagnostics Inc. reported for 2026 q2
SEC form 8
2026-05-14 12:05 ET
Lucid Diagnostics Inc. published news for 2026 q1
SEC form 8
2026-05-14 12:05 ET
Lucid Diagnostics Inc. published news for 2026 q1
SEC form 10
2026-05-13 20:31 ET
Lucid Diagnostics Inc. reported for 2026 q1
SEC form 8
2026-04-24 20:30 ET
Lucid Diagnostics Inc. published news for 2026 q1
SEC form 8
2026-04-24 20:30 ET
Lucid Diagnostics Inc. published news for 2026 q1
SEC form 8
2026-04-23 20:30 ET
Lucid Diagnostics Inc. published news for 2026 q1
SEC form 8
2026-04-23 20:30 ET
Lucid Diagnostics Inc. published news for 2026 q1
SEC form 8
2026-04-23 20:30 ET
Lucid Diagnostics Inc. published news for 2026 q1
SEC form 8
2026-04-23 20:30 ET
Lucid Diagnostics Inc. published news for 2026 q1
SEC form 8
2026-03-26 12:00 ET
Lucid Diagnostics Inc. published news for 2025 q4
SEC form 8
2026-03-26 12:00 ET
Lucid Diagnostics Inc. reported for 2025 q4
SEC form 10
2026-03-25 20:56 ET
Lucid Diagnostics Inc. reported for 2025 q4
SEC form 8
2025-11-12 08:15 ET
Lucid Diagnostics Inc. published news for 2025 q3
SEC form 8
2025-11-12 08:15 ET
Lucid Diagnostics Inc. reported for 2025 q3
SEC form 10
2025-11-12 08:01 ET
Lucid Diagnostics Inc. reported for 2025 q3
SEC form 8
2025-09-11 13:27 ET
Lucid Diagnostics Inc. published news for 2025 q2
SEC form 8
2025-09-11 13:27 ET
Lucid Diagnostics Inc. published news for 2025 q2
SEC form 8
2025-09-10 13:15 ET
Lucid Diagnostics Inc. published news for 2025 q2
SEC form 8
2025-09-10 13:15 ET
Lucid Diagnostics Inc. published news for 2025 q2
SEC form 8
2025-09-10 13:15 ET
Lucid Diagnostics Inc. published news for 2025 q2
SEC form 8
2025-09-10 13:15 ET
Lucid Diagnostics Inc. published news for 2025 q2
SEC form 8
2025-09-10 13:15 ET
Lucid Diagnostics Inc. published news for 2025 q2
SEC form 8
2025-08-13 12:00 ET
Lucid Diagnostics Inc. published news for 2025 q2
SEC form 8
2025-08-13 12:00 ET
Lucid Diagnostics Inc. reported for 2025 q2
SEC form 10
2025-08-12 21:29 ET
Lucid Diagnostics Inc. reported for 2025 q2
SEC form 8
2025-06-18 21:00 ET
Lucid Diagnostics Inc. published news for 2025 q1
SEC form 8
2025-05-30 20:35 ET
Lucid Diagnostics Inc. published news for 2025 q1
SEC form 8
2025-05-30 20:35 ET
Lucid Diagnostics Inc. published news for 2025 q1
SEC form 8
2025-05-30 20:35 ET
Lucid Diagnostics Inc. published news for 2025 q1
SEC form 8
2025-05-14 00:00 ET
Lucid Diagnostics Inc. published news for 2025 q1
SEC form 8
2025-05-14 00:00 ET
Lucid Diagnostics Inc. reported for 2025 q1
SEC form 10
2025-05-13 20:58 ET
Lucid Diagnostics Inc. reported for 2025 q1
SEC form 10
2025-05-13 00:00 ET
Lucid Diagnostics Inc. reported for 2025 q1
SEC form 8
2025-04-25 20:44 ET
Lucid Diagnostics Inc. published news for 2025 q1
SEC form 8
2025-04-25 20:44 ET
Lucid Diagnostics Inc. published news for 2025 q1
SEC form 8
2025-04-11 13:25 ET
Lucid Diagnostics Inc. published news for 2025 q1
SEC form 8
2025-04-11 13:25 ET
Lucid Diagnostics Inc. published news for 2025 q1
SEC form 8
2025-04-10 12:30 ET
Lucid Diagnostics Inc. published news for 2025 q1
SEC form 8
2025-04-10 12:30 ET
Lucid Diagnostics Inc. published news for 2025 q1
SEC form 8
2025-04-10 12:30 ET
Lucid Diagnostics Inc. published news for 2025 q1
SEC form 8
2025-04-10 12:30 ET
Lucid Diagnostics Inc. published news for 2025 q1
SEC form 8
2025-04-10 12:30 ET
Lucid Diagnostics Inc. published news for 2025 q1
SEC form 8
2025-03-25 00:00 ET
Lucid Diagnostics Inc. published news for 2024 q4
SEC form 8
2025-03-25 00:00 ET
Lucid Diagnostics Inc. reported for 2024 q4
SEC form 10
2025-03-24 08:00 ET
Lucid Diagnostics Inc. reported for 2024 q4
SEC form 10
2025-03-24 00:00 ET
Lucid Diagnostics Inc. reported for 2024 q4
SEC form 8
2025-03-05 21:30 ET
Lucid Diagnostics Inc. published news for 2024 q4
SEC form 8
2025-03-05 21:30 ET
Lucid Diagnostics Inc. published news for 2024 q4
SEC form 8
2025-03-04 13:15 ET
Lucid Diagnostics Inc. published news for 2024 q4
SEC form 8
2025-03-04 13:15 ET
Lucid Diagnostics Inc. published news for 2024 q4
SEC form 8
2025-03-04 13:15 ET
Lucid Diagnostics Inc. published news for 2024 q4
SEC form 8
2025-03-04 13:15 ET
Lucid Diagnostics Inc. published news for 2024 q4
SEC form 8
2025-03-04 13:15 ET
Lucid Diagnostics Inc. published news for 2024 q4
SEC form 8
2025-03-04 12:56 ET
Lucid Diagnostics Inc. published news for 2024 q4
SEC form 8
2025-02-24 23:38 ET
Lucid Diagnostics Inc. published news for 2024 q4
SEC form 8
2024-11-13 08:15 ET
Lucid Diagnostics Inc. published news for 2024 q3
SEC form 8
2024-11-13 08:15 ET
Lucid Diagnostics Inc. reported for 2024 q3
SEC form 10
2024-11-12 16:36 ET
Lucid Diagnostics Inc. reported for 2024 q3
SEC form 10
2024-11-12 00:00 ET
Lucid Diagnostics Inc. reported for 2024 q3
SEC form 10
2024-08-12 08:31 ET
Lucid Diagnostics Inc. reported for 2024 q2
SEC form 8
2024-08-12 08:15 ET
Lucid Diagnostics Inc. published news for 2024 q2
SEC form 8
2024-08-12 08:15 ET
Lucid Diagnostics Inc. reported for 2024 q2
SEC form 10
2024-08-12 00:00 ET
Lucid Diagnostics Inc. reported for 2024 q2
SEC form 8
2024-05-14 06:05 ET
Lucid Diagnostics Inc. published news for 2024 q1
SEC form 8
2024-05-14 06:05 ET
Lucid Diagnostics Inc. reported for 2024 q1
SEC form 10
2024-05-13 08:21 ET
Lucid Diagnostics Inc. reported for 2024 q1
SEC form 10
2024-05-13 00:00 ET
Lucid Diagnostics Inc. reported for 2024 q1
SEC form 10
2024-03-25 17:21 ET
Lucid Diagnostics Inc. reported for 2023 q4
SEC form 10
2024-03-25 00:00 ET
Lucid Diagnostics Inc. reported for 2023 q4
SEC form 8
2023-11-13 21:40 ET
Lucid Diagnostics Inc. reported for 2023 q3
SEC form 10
2023-11-13 17:15 ET
Lucid Diagnostics Inc. reported for 2023 q3
SEC form 10
2023-11-13 00:00 ET
Lucid Diagnostics Inc. reported for 2023 q3
SEC form 10
2023-08-14 16:45 ET
Lucid Diagnostics Inc. reported for 2023 q2
SEC form 10
2023-08-14 00:00 ET
Lucid Diagnostics Inc. reported for 2023 q2
SEC form 6
2023-06-21 17:00 ET
Lucid Diagnostics Inc. published news for 2023 q1
SEC form 10
2023-05-15 16:25 ET
Lucid Diagnostics Inc. reported for 2023 q1
SEC form 10
2023-05-15 00:00 ET
Lucid Diagnostics Inc. reported for 2023 q1
SEC form 6
2023-05-01 09:00 ET
Lucid Diagnostics Inc. published news for 2023 q1
SEC form 6
2023-04-19 17:03 ET
Lucid Diagnostics Inc. published news for 2023 q1
SEC form 6
2023-04-03 09:11 ET
Lucid Diagnostics Inc. published news for 2023 q1
SEC form 6
2023-03-24 17:17 ET
Lucid Diagnostics Inc. published news for 2022 q4
SEC form 6
2023-03-14 17:00 ET
Lucid Diagnostics Inc. published news for 2022 q4
SEC form 10
2023-03-14 00:00 ET
Lucid Diagnostics Inc. reported for 2022 q4
SEC form 10
2023-03-13 18:36 ET
Lucid Diagnostics Inc. reported for 2022 q4
SEC form 6
2023-03-13 17:00 ET
Lucid Diagnostics Inc. published news for 2022 q4
SEC form 6
2023-02-17 16:30 ET
Lucid Diagnostics Inc. published news for 2022 q4
SEC form 6
2023-02-16 16:30 ET
Lucid Diagnostics Inc. published news for 2022 q4
SEC form 6
2023-01-18 08:36 ET
Lucid Diagnostics Inc. published news for 2022 q4
SEC form 6
2022-12-02 17:20 ET
Lucid Diagnostics Inc. published news for 2022 q3
SEC form 6
2022-11-14 17:23 ET
Lucid Diagnostics Inc. published news for 2022 q3
SEC form 10
2022-11-14 16:08 ET
Lucid Diagnostics Inc. reported for 2022 q3
SEC form 10
2022-11-14 00:00 ET
Lucid Diagnostics Inc. reported for 2022 q3
SEC form 8
2022-11-14 00:00 ET
Lucid Diagnostics Inc. published news for 2022 q3
SEC form 10
2022-08-15 18:11 ET
Lucid Diagnostics Inc. reported for 2022 q2
SEC form 6
2022-08-15 18:03 ET
Lucid Diagnostics Inc. published news for 2022 q2
SEC form 10
2022-08-15 00:00 ET
Lucid Diagnostics Inc. reported for 2022 q2
SEC form 8
2022-08-15 00:00 ET
Lucid Diagnostics Inc. published news for 2022 q2
SEC form 6
2022-08-02 16:30 ET
Lucid Diagnostics Inc. published news for 2022 q2
SEC form 6
2022-06-22 09:00 ET
Lucid Diagnostics Inc. published news for 2022 q1
SEC form 10
2022-05-16 17:18 ET
Lucid Diagnostics Inc. reported for 2022 q1
SEC form 10
2022-05-16 00:00 ET
Lucid Diagnostics Inc. reported for 2022 q1
SEC form 6
2022-05-12 17:15 ET
Lucid Diagnostics Inc. published news for 2022 q1
SEC form 8
2022-05-12 00:00 ET
Lucid Diagnostics Inc. published news for 2022 q1
SEC form 6
2022-05-09 16:47 ET
Lucid Diagnostics Inc. published news for 2022 q1
SEC form 6
2022-05-02 09:25 ET
Lucid Diagnostics Inc. published news for 2022 q1
SEC form 6
2022-04-22 16:30 ET
Lucid Diagnostics Inc. published news for 2022 q1
SEC form 10
2022-04-06 00:00 ET
Lucid Diagnostics Inc. published news for 2021 q4
SEC form 10
2022-04-05 21:21 ET
Lucid Diagnostics Inc. published news for 2021 q4
SEC form 6
2022-04-04 18:28 ET
Lucid Diagnostics Inc. published news for 2022 q1
SEC form 6
2022-04-01 16:30 ET
Lucid Diagnostics Inc. published news for 2022 q1
SEC form 6
2022-04-01 16:05 ET
Lucid Diagnostics Inc. published news for 2022 q1
SEC form 6
2022-03-29 17:25 ET
Lucid Diagnostics Inc. published news for 2021 q4
SEC form 6
2022-03-28 17:11 ET
Lucid Diagnostics Inc. published news for 2021 q4
SEC form 8
2022-03-28 00:00 ET
Lucid Diagnostics Inc. published news for 2021 q4
SEC form 6
2022-03-23 16:30 ET
Lucid Diagnostics Inc. published news for 2021 q4
SEC form 6
2022-03-07 08:33 ET
Lucid Diagnostics Inc. published news for 2021 q4
SEC form 6
2022-03-03 08:26 ET
Lucid Diagnostics Inc. published news for 2021 q4
SEC form 6
2022-01-20 16:15 ET
Lucid Diagnostics Inc. published news for 2021 q4
SEC form 6
2022-01-07 09:00 ET
Lucid Diagnostics Inc. published news for 2021 q4
SEC form 6
2021-12-02 08:30 ET
Lucid Diagnostics Inc. published news for 2021 q3
SEC form 10
2021-11-23 16:11 ET
Lucid Diagnostics Inc. published news for 2021 q3
SEC form 10
2021-11-23 00:00 ET
Lucid Diagnostics Inc. published news for 2021 q3
SEC form 6
2021-11-12 16:00 ET
Lucid Diagnostics Inc. published news for 2021 q3
SEC form 6
2021-10-29 07:00 ET
Lucid Diagnostics Inc. published news for 2021 q3
SEC form 6
2021-10-18 17:26 ET
Lucid Diagnostics Inc. published news for 2021 q3